ArticleClinical, cosmetic and investigational dermatology2025
Global Research Trends in Apremilast for Psoriasis: A Bibliometric Analysis (2008-2024).
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Psoriasis is a chronic, immune-mediated skin disease that significantly affects patients' quality of life. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, has emerged as a promising treatment for moderate to severe psoriasis, offering an alternative to biologics with a favorable safety profile. This study analyzes global research trends, key contributors, and emerging focus areas concerning apremilast in the treatment of psoriasis. Patients and Methods: Publications related to apremilast and psoriasis from 2008 to 2024 were retrieved from the Web of Science Core Collection (WoSCC). Bibliometric and visual analyses were performed using tools such as VOSviewer, CiteSpace, and R 4.3.3. Results: A total of 437 publications on apremilast and psoriasis were identified. The United States led with 158 publications, followed by Japan with 39 and Italy with 33. Celgene Corporation was the most productive institution, contributing 96 articles. The top journals include Conclusion: This bibliometric analysis demonstrates that research on Apremilast for psoriasis has evolved from clinical trials focused on efficacy and safety to broader applications in real-world settings, including nail psoriasis and pathogenesis. Future research is likely to concentrate on long-term outcomes, optimizing treatment regimens, and addressing unmet needs in psoriasis management, particularly among specific patient subgroups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.